

CURRICULUM VITAE

ARKADIUSZ Z. DUDEK, M.D, PH.D.

PROFESSIONAL ADDRESS

Health Partners Cancer Care Center
Suite 1161 Mail Stop 11101G
640 Jackson Street, St. Paul, MN 55101
Tel: 651 254-3321
Fax: 651 254-3102
E-mail Address: Arkadiusz.Z.Dudek@healthpartners.com

IDENTIFYING INFORMATION

Education

Degree	Institution	Date Degree Granted
Matura (Secondary School Certification) XIV Liceum Ogolnoksztalcace (Equivalent to High School)	Warsaw, POLAND	1982
M.D.	Medical University of Warsaw Warsaw, POLAND	1989
Ph.D.	Military Medical Institute Medical Oncology Warsaw, POLAND	1998
Externship in Cardiology Groupe Hospitalier Pitie-Salpetriere, Paris, FRANCE		06/1988-09/1988
Internship in Internal Medicine Polyclinic Medical Center, Harrisburg, PA		07/1991-06/1992
Residency in Internal Medicine Polyclinic Medical Center, Harrisburg, PA		07/1992-06/1994
Visiting Residency in Gastroenterology The Milton S. Hershey Medical Center University Hospital, Penn State College of Medicine Hershey, PA		04/1993-05/1993
Clinical Fellowship: Bone Marrow Transplant Unit Johns Hopkins Hospital, Baltimore, MD		05/1993-06/1993
Visiting Residency in Rheumatology The Milton S. Hershey Medical Center Penn State College of Medicine, Hershey, PA		03/1994-04/1994

Arkadiusz Z. Dudek

Fellowship: Hematology, Oncology and Transplantation
University of Minnesota, Minneapolis, MN

07/1994-12/1997

Certifications, Licenses

2008 – American Board of Oncology, Recertification
2008 – American Board of Hematology, Recertification
2005 – American Board of Internal Medicine, Recertification
1998 – American Board of Medical Oncology
1997 – Fellowship in Hematology and Oncology Certification
1997 – American Board of Hematology
1994 – American Board of Internal Medicine
1994 – Minnesota State Board of Medical Examiners (active)
1994 – DEA registration (active)
1991 – Pennsylvania State Board of Medical Examiners (inactive)

Academic Appointments

2016-present Affiliate Professor, Department of Medicine,
University of Minnesota
2015-present Adjunct Professor, Biopharmaceutical Sciences,
University of Illinois at Chicago
2013- Present Professor of Medicine (tenured), University of Illinois at Chicago
1997 – 2012 University of Minnesota, School of Medicine (Twin Cities)
2008 – 2012 Associate Professor of Medicine (non-tenured)
1998 – 2008 Assistant Professor of Medicine
1997 – 1998 Instructor of Medicine

Academic Administrative Appointments

2016 -2017 Senator, University of Illinois at Chicago,
Member of the Senate Budget, Planning and Priorities Committee
2016 Co-Leader, Clinical Science Group
University of Illinois Cancer Center
2013 – 2016 Director, Clinical Trials Office
University of Illinois Cancer Center
2013 – 2016 Director, Phase 1 Unit
University of Illinois Cancer Center
2013 – 2016 Leader, Cancer Target and Therapeutics Program
Cancer Center, University of Illinois
2013 –2016 Member, Executive Committee
Cancer Center, University of Illinois
2012 -2013 Member, Executive Committee
Masonic Cancer Center, University of Minnesota
2008 – 2012 Director, Solid Tumor Oncology, Cancer Experimental Therapeutics Initiative
Masonic Cancer Center, University of Minnesota

A. Dudek

- 2005 – 2008 Clinical Research Director, Division Hematology, Oncology and Transplantation
University of Minnesota
- 1998 – 2012 Co-Chair, Thoracic Oncology Program
University of Minnesota Comprehensive Cancer Center

Clinical/Hospital Appointments

- 2013 – Present Staff Physician
University of Illinois at Chicago
- 1997 – 2012 Staff Physician
University of Minnesota Medical Center, Fairview

Consulting Positions

- 2015 – 2016 Adhaere Pharmaceuticals, Inc, Chief Medical Officer
2014 – Present GeneSegues, Inc., Scientific Advisory Board
2014 – Present Martell Diagnostic Laboratories, Chairman of Medical Advisory Board
2014 – 2015 Vista Oncology, LLC, Board Member
2013 – Present Vanquish Oncology, Chairman of Clinical Advisory Board
2010 – Present IGF Oncology, Board Member
2007 – Present Biothera, Clinical Advisory Board Member
2005 – 2010 IGF Oncology, Consultant
2004 – 2010 Medisyn Technologies, Consultant

Current Membership and Offices in Professional Organizations

- 2002 – Present Member, Fellow of American College of Physicians
2013 – Present Member, University of Illinois Cancer Center Executive Committee
2008 – Present Member, International Association for the study of Lung Cancer
1999 – 2012 Member, University of Minnesota Cancer Center
1998 – Present Member, European Society of Medical Oncology
1998 – 2009 Member, European Hematology Association
1998 – Present Member, American Association for Cancer Research
1998 – 2009 Member, American Association for the Advancement of Science
1997 – Present Member, American Society of Hematology
1997 – Present Member, American Society of Clinical Oncology


HONORS AND AWARDS FOR RESEARCH WORK, TEACHING, PUBLIC ENGAGEMENT, AND SERVICE

University of Illinois

- 2014 Hematology and Oncology Fellowship Program:
Mentor Award

University of Minnesota

- 2010 Hematology, Oncology, and Transplantation Fellowship Program:
Outstanding Academic Mentor Award
2005 - 2007 University of Minnesota Cancer Center Clinical Scholar Award



2005 University of Minnesota, Department of Medicine, Clinical Excellence Award
2004 University of Minnesota Cancer Center Award of Recognition

External Sources

2011 Champions of Care Honor, Fairview Foundation
2006 - 2009 American Medical Association: Physicians' Recognition Award
1999 Fellow American College of Physicians

RESEARCH AND SCHOLARSHIP

Grants and Contracts

External Sources (federal {NIH, NSF, DEO, etc.} or state grants, foundation awards, etc.)

National Clinical Research


Investigator status: Study Chair
External Agency: Cancer and Leukemia Group B
Project title: CALGB 30901: Randomized Phase II Study of Maintenance Pemetrexed vs Observation for Patients with Malignant Mesothelioma without Progression after First-Line Chemotherapy
Dates: 2009 - current
Direct costs/year: N/A
% Funded salary support: N/A

Investigator status: Study Chair
External Agency: Cancer and Leukemia Group B
Project title: CALGB 30601: A Phase II study of Dasatinib (NSC #732517, IND #73969) in patients with previously treated Malignant Mesothelioma
Dates: 2006 - 2011
Direct costs/year: N/A
% Funded salary support: N/A

Clinical Research Investigator Initiated Grants

Investigator status: Principal investigator
External Agency: Big Ten Cancer Research Consortium
Project title: Phase Ib and Phase II Studies of anti-PD-1 Antibody MK-3475 in Combination with Bevacizumab for the Treatment of Metastatic Renal Cell Carcinoma: Big Ten Cancer Research Consortium BTCRC-GU14-003.
Dates: 2015 - ongoing
Direct costs/year: \$999,342
% Funded salary support: 5%

Investigator status: Principal investigator
External Agency: Millennium, The Takeda Oncology Company
Project title: Phase I Study of Aurora A Kinase Inhibitor (MLN8237) Given in Combination with Selective VEGFR Inhibitor Pazopanib (Votrient) for Therapy of Solid Tumors.
Dates: 2013 - ongoing
Direct costs/year: \$545,762
% Funded salary support: 5%



Investigator status: Principal investigator
External Agency: Bristol-Myers Squibb and GlaxoSmithKline Pharmaceuticals
Project title: 2009LS001. Phase I Study of Pazopanib and Ixabepilone in Patients With Solid Tumor. IND Number: 106653.
Dates: 2009 -2012
Direct costs/year: \$ 411,107
% Funded salary support: 5%

Clinical Research Industry Sponsored Grants

Investigator status: Principal investigator
External Agency: Argos Therapeutics, Inc.
Project title: AGS-003-007: An International Phase 3 Randomized Trial of Autologous Dendritic Cell Immunotherapy (AGS-003) Plus Standard Treatment of Advanced Renal Cell Carcinoma (ADAPT)
Dates: 6/2013-6/2018
Direct costs/year: \$ 142,493,
% Funded salary support: 1%


Investigator status: Principal investigator
External Agency: NewLink Genetics & Dendreon Corporation
Project title: PRO-01: A Randomized, Double-Blind Phase II Study of Sipuleucel-T (Provenge®) Followed by Indoximod or Placebo in the Treatment of Patients with Asymptomatic or Minimally Symptomatic Metastatic Castration Resistant Prostate
Dates: 7/2013-7/2016
Direct costs: \$ 163,103
% Funded salary support: 1%

Grants –Basic Research

Investigator status: Co-investigator
External Agency: Illinois Department of Public Health - Penny Severns Cancer Research Fund
Project title: Activity of P-SSM in Metastatic Malignant Melanoma
Dates: 2013 - 2014
Direct costs/year: \$150,000
% Funded salary support: 1%

Investigator status: Principal investigator
External Agency: Randy Shaver Cancer Research and Community Fund
Project title: CSPG4 activation of PI3K/mTOR pathway in melanoma
Dates: 2011 - 2012
Direct costs/year: \$22,224
% Funded salary support: 1%

Investigator status: Principal investigator
External Agency: Randy Shaver Cancer Research and Community Fund
Project title: Melanoma Proteoglycan Function in Melanoma with Mutated BRAF
Dates: 2010 - 2011

 Arkadiusz Dudek

Direct costs/year: \$ 25,178
% Funded salary support: 10%

Investigator status: Principal investigator
External Agency: Susan G. Komen Breast Cancer Foundation
Project title: Blood Outgrowth Endothelial Cells Based Cancer Gene Therapy
Dates: 2006 - 2008
Direct costs/year: \$200,000
% Funded salary support: 10%

Investigator status: Principal investigator
External Agency: Eli Lilly and Company
Project title: Preclinical study of protein kinase C inhibitor, enzaustarin in combination with radiation
Dates: 2006
Direct costs/year: \$30,000
% Funded salary support: 5%

Investigator status: Principal investigator
External Agency: Pardee Foundation
Project title: Blood Outgrowth Endothelial Cells Based Cancer Gene Therapy
Dates: 2005
Direct costs/year: \$100,000
% Funded salary support: 5%


Investigator status: Principal investigator
External Agency: Susan G. Komen Breast Cancer Foundation
Project title: Blood Outgrowth Endothelial Cells Based Cancer Gene Therapy
Dates: 2002 - 2004
Direct costs/year: \$67,000
% Funded salary support: 10%

University Sources

Clinical Research Investigator Initiated Grants

Investigator status: Principal investigator
External Agency: Masonic Cancer Center
Project title: 2006LS046. A Randomized Phase II Study of IL-2 With or Without an Allogeneic Large Multivalent Immunogen (LMI) Vaccine for the Treatment of Stage IV Melanoma. IND # 10156.
Dates: 2006 - 2011
Direct costs: \$ 96,813

Investigator status: Co-investigator
Agency: SP3 proposal, Masonic Cancer Center, University of Minnesota
Project title: Genomic Signatures for Colorectal Cancer
Dates: 2012 - 2013
Direct costs: \$ 240,000
% Funded salary support: (2% unpaid)

 Arkadiusz Dudek

8. Ojevwe FO, Ojevwe CD, Zacny JP, **Dudek AZ**, Lin A, Kohlitz P. Treatment of Multiple Unresectable Basal Cell Carcinomas from Gorlin-Goltz Syndrome: a Case Report. *Anticancer Res.* 2015;35(3):1777-81.
Impact Factor: 1.725 *Citation Index: -*
9. Javaid S, Terai K, **Dudek AZ**. Chondroitin Sulfate Proteoglycan-4 Does Not Protect Melanoma Cells During Inhibition of PI3K and mTOR Pathways. *Anticancer Res.* 2015;35(3):1279-84.
Impact Factor: 1.725 *Citation Index: -*
10. Kim C, Economou S, Amatruda TT, Martin JC, **Dudek AZ**. Prognostic significance of microscopic tumor burden in sentinel lymph node in patients with cutaneous melanoma. *Anticancer Res.* 2015;35(1):301-9.
Impact Factor: 1.725 *Citation Index: -*
11. Gummadi T1, Zhang BY, Valpione S, Kim C, Kottschade LA, Mittapalli RK, Chiarion-Sileni V, Pigozzo J, Elmquist WF, **Dudek AZ**. Impact of BRAF mutation and BRAF inhibition on melanoma brain metastases. *Melanoma Res.* 2015;25(1):75-9.
Impact Factor: 2.518 *Citation Index: -*
12. Reddy SP, Natarajan V, **Dudek AZ**. MARCKS Is Marked in Combating Lung Cancer Growth and Acquired Resistance. *Am J Respir Crit Care Med.* 2014;190(10):1084-6. [PMCID: PMC4299642]
Impact Factor: 11.986 *Citation Index: -*
13. Litvan J, Aghazarian M, Wiley E, Guleria S, **Dudek AZ**. Primary peritoneal angiosarcoma: a case report. *Anticancer Res.* 2014;34(9):5001-6.
Impact Factor: 1.725 *Citation Index: -*
14. Masri SC, Misselt AJ, **Dudek A**, Konety SH. Radiation recall reaction causing cardiotoxicity. *J Cardiovasc Magn Reson.* 2014;16(1):25. [PMCID: PMC4023176]
Impact Factor: 3.717 *Citation Index: not yet published*
15. Ganesan C, Obulareddy SJ, Fischer JH, Antonysamy MA, Jha G, Bliss RL, **Dudek AZ**. Phase I Study of Pazopanib and Ixabepilone in Patients With Solid Tumors. *Am J Clin Oncol.* 2014 Feb 26.
Impact Factor: 2.005 *Citation Index: not yet published*
16. Abern MR1, Scosyrev E, Tsivian M, Messing EM, Polascik TJ, **Dudek AZ**. Survival of patients undergoing cytoreductive surgery for metastatic renal cell carcinoma in the targeted-therapy era. *Anticancer Res.* 2014;34(5):2405-11.
Impact Factor: 1.725 *Citation Index: -*
17. Jha G, Miller JS, Curtsinger JM, Zhang Y, Mescher MF, **Dudek AZ**. Randomized Phase II Study of IL-2 With or Without an Allogeneic Large Multivalent Immunogen Vaccine for the Treatment of Stage IV Melanoma. *Amer J Clin Oncol.* 2014;37(3):261-5.
Impact Factor: 2.005 *Citation Index: -*
18. **Dudek AZ**, Kumar P, Thaw SS, Cao Q, Pawloski P, Larson T. Phase II Study of Biweekly Carboplatin, Gemcitabine, and Bevacizumab as First-line Treatment in Patients with Stage IIIB/IV NSCLC. *Amer J Clin Oncol.* 2014;37(2):140-3.
Impact Factor: 2.005 *Citation Index: -*
19. Butts C1, Socinski MA2, Mitchell PL3, Thatcher N4, Havel L5, Krzakowski M6, Nawrocki S7, Ciuleanu TE8, Bosquée L9, Trigo JM10, Spira A11, Tremblay L12, Nyman J13, Ramlau R14, Wickart-Johansson G15, Ellis P16, Gladkov O17, Pereira JR18, Eberhardt WE19, Helwig C20, Schröder A20, Shepherd FA21; START trial team (**AZ Dudek**). Tecemotide (L-BLP25) versus placebo after chemoradiotherapy for stage III non-small-cell lung cancer (START): a randomised, double-blind, phase 3 trial. *Lancet Oncol.* 2014;15(1):59-68.
Impact Factor: 22.589 *Citation Index: 4*
20. Dudek AZ, Kumar P, H Thaw SS, Cao Q, Pawloski P, Larson T. Phase II Study of Biweekly Carboplatin, Gemcitabine, and Bevacizumab as First-line Treatment in Patients with Stage IIIB/IV NSCLC. *Am J Clin Oncol.* 2014;37(2):140-3.
21. Khatri A, Williams BW, Fisher J, Brundage RC, Gurvich VJ, Lis LG, Skubitz KM, **Dudek AZ**, Greeno EW, Kratzke RA, Lamba JK, Kirstein MN. SLC28A3 genotype and gemcitabine rate of

- infusion affect dFdCTP metabolite disposition in patients with solid tumours. *Br J Cancer* 2014;110(2):304-12. [PMCID: PMC3899768]
Impact Factor: 5.042 *Citation Index: -*
22. Litterman AJ, **Dudek AZ**, Largaespada DA. Alkylating chemotherapy may exert a uniquely deleterious effect upon neo-antigen-targeting anticancer vaccination. *Oncoimmunology* 2013;2(10):e26294. [PMCID:PMC3827073]
Impact Factor: 4.090 *Citation Index: 0*
23. Zwolak P, **Dudek AZ**. Antineoplastic activity of zoledronic acid and denosumab. *Anticancer Res.* 2013;33(8):2981-8.
Impact Factor: 1.725 *Citation Index: 0*
24. Powell SF, Beitinjaneh A, Tessema M, Bliss RL, Kratzke RA, Leach J, **Dudek AZ**. Phase II Study of Topotecan and Bevacizumab in Advanced, Refractory Non-small-cell Lung Cancer. *Clin Lung Cancer* 2013;14(4):495-501.
Impact Factor: 2.944 *Citation Index: 0*
25. Litterman AJ, Zellmer DM, Grinnen KL, Hunt MA, **Dudek AZ**, Salazar AM, Ohlfest JR. Profound Impairment of Adaptive Immune Responses by Alkylating Chemotherapy. *J Immunol* 2013;190(12):6259-68. [PMCID:PMC3680135]
Impact Factor: 5.788 *Citation Index: 1*
26. Sreenivasan V, **Dudek AZ**. Dystonia in a patient with melanoma metastatic to the brain treated with high-dose interleukin-2, radiation therapy, and levetiracetam. *Case Rep Oncol.* 2013;6(1):78-83. [PMCID:PMC3573788]
Impact Factor: 0.15 (SJR) *Citation Index: 0*
27. Endrizzi B, Ahmed RL, Ray T, **Dudek A**, Lee P. Capecitabine to reduce nonmelanoma skin carcinoma burden in solid organ transplant recipients. *Dermatol Surg.* 2013;39(4):634-45.
Impact Factor: 1.798 *Citation Index: 2*
28. Jones R, Vuky J, Elliott T, Mead G, Arranz JA, Chester J, Chowdhury S, **Dudek AZ**, Müller-Mattheis V, Grimm MO, Gschwend JE, Wülfing C, Albers P, Li J, Osmukhina A, Skolnik J, Hudes G. Phase II study to assess the efficacy, safety and tolerability of the mitotic spindle kinesin inhibitor AZD4877 in patients with recurrent advanced urothelial cancer. *Invest New Drugs* 2013;31(4):1001-7.
Impact Factor: 3.357 *Citation Index: 3*
29. **Dudek AZ**, Raza A, Chi M, Singhal M, Oberoi R, Mittapalli RK, Agarwal S, Elmquist WF. Brain Metastases from Renal Cell Carcinoma in the Era of Tyrosine Kinase Inhibitors. *Clin Genitourin Cancer* 2012;11(2):155-60.
Impact Factor: 2.605 *Citation Index: 3*
30. Mittapalli RK, Vaidhyanathan S, **Dudek AZ**, Elmquist WF. Mechanisms Limiting Distribution of the BRAFV600E Inhibitor Dabrafenib to the Brain: Implications for the Treatment of Melanoma Brain Metastases. *J Pharmacol Exp Ther.* 2012;344(3):655-64. [PMCID:PMC3583506]
Impact Factor: 3.828 *Citation Index: 8*
Impact Factor: 2.005 *Citation Index: not yet published*
31. Mitra AK, Kirstein MN, Khatri A, Skubitz KM, **Dudek AZ**, Greeno EW, Kratzke RA, Lamba JK. Pathway-based pharmacogenomics of gemcitabine pharmacokinetics in patients with solid tumors. *Pharmacogenomics* 2012;13(9):1009-21.
Impact Factor: 3.974 *Citation Index: 5*
32. Thumbigere-Math V, Tu L, Huckabay S, **Dudek AZ**, Lunos S, Basi DL, Hughes PJ, Leach JW, Swenson KK, Gopalakrishnan R. A Retrospective Study Evaluating Frequency and Risk Factors of Osteonecrosis of the Jaw in 576 Cancer Patients Receiving Intravenous Bisphosphonates. *Am J Clin Oncol.* 2012;35(4):386-92.
Impact Factor: 2.005 *Citation Index: 5*
33. Clément-Duchêne C, Natale RB, Jahan T, Krupitskaya Y, Osarogiagbon R, Sanborn RE, Bernstein ED, **Dudek AZ**, Latz JE, Shi P, Wakelee HA A phase II study of enzastaurin in combination with

- erlotinib in patients with previously treated advanced non-small cell lung cancer. *Lung Cancer* 2012;78(1):57-62. [Open Access]
Impact Factor: 3.434 *Citation Index: 2*
34. Yoseph B, Chi M, Truskinovsky AM, **Dudek AZ**. Large-cell neuroendocrine carcinoma of the cervix. *Rare Tumors* 2012;4(1):e18. [PMCID:PMC3325745]
Impact Factor: 1. *Citation Index: 0*
35. Chi M, **Dudek AZ**, Wind KP. Primary hepatic leiomyosarcoma in adults: analysis of prognostic factors. *Onkologie* 2012;35(4):210-4.
Impact Factor: 0.868 *Citation Index: 0*
36. Wang K, Bodempudi V, Liu Z, Borrego-Diaz E, Yamoutpoor F, Meyer A, Woo RA, Pan W, **Dudek AZ**, Olyae MS, Esfandyari T, Farassati F. Inhibition of mesothelin as a novel strategy for targeting cancer cells. *PLoS One* 2012;7(4):e33214. [PMCID:PMC3317639]
Impact Factor: 4.092 *Citation Index: 10*
37. Yang JC, Shih JY, Su WC, Hsia TC, Tsai CM, Ou SH, Yu CJ, Chang GC, Ho CL, Sequist LV, **Dudek AZ**, Shahidi M, Cong XJ, Lorence RM, Yang PC, Miller VA. Afatinib for patients with lung adenocarcinoma and epidermal growth factor receptor mutations (LUX-Lung 2): a phase 2 trial. *Lancet Oncol* 2012;13(5):539-48.
Impact Factor: 22.589 *Citation Index: 86*
38. **Dudek AZ**, Pang H, Kratzke RA, Otterson GA, Hodgson L, Vokes EE, Kindler HL; Cancer and Leukemia Group B. Phase II Study of Dasatinib in Patients with Previously Treated Malignant Mesothelioma (Cancer and Leukemia Group B 30601): A Brief Report. *J Thorac Oncol* 2012;7(4):755-9. [PMCID:PMC3308128]
Impact Factor: 3.661 *Citation Index: 4*
39. Wang H, Cao Q, **Dudek AZ**. Phase II Study of Panobinostat and Bortezomib in Patients with Pancreatic Cancer Progressing on Gemcitabine-based Therapy. *Anticancer Res.* 2012;32(3):1027-31.
Impact Factor: 1.725 *Citation Index: 7*
40. Jahan T, Gu L, Kratzke R, **Dudek A**, Otterson GA, Wang X, Green M, Vokes EE, Kindler HL. Vatalanib in malignant mesothelioma: A phase II trial by the Cancer and Leukemia Group B (CALGB 30107). *Lung Cancer* 2012;76(3):393-6.
Impact Factor: 3.434 *Citation Index: 10*
41. Zhang H, Li W, Franklin MJ, **Dudek AZ**. Polymorphisms in DNA repair gene XRCC1 and skin cancer risk: a meta-analysis. *Anticancer Res.* 2011;31(11):3945-52.
Impact Factor: 1.725 *Citation Index: 15*
42. Liu SV, Truskinovsky AM, **Dudek AZ**, Ramanathan RK. Metastatic Clear Cell Adenocarcinoma of the Urethra in a Male Patient: Report of a Case. *Clin Genitourin Cancer* 2011;10(1):47-9.
Impact Factor: 2.605 *Citation Index: 0*
43. Ready NE, **Dudek AZ**, Pang HH, Hodgson LD, Graziano SL, Green MR, Vokes EE. Cisplatin, Irinotecan, and Bevacizumab for Untreated Extensive-Stage Small-Cell Lung Cancer: CALGB 30306, a Phase II Study. *J Clin Oncol.* 2011;29(33):4436-41. [PMCID:PMC3221525]
Impact Factor: 18.372 *Citation Index: 22*
44. Price MA, Colvin Wanshura LE, Yang J, Carlson J, Xiang B, Li G, Ferrone S, **Dudek AZ**, Turley EA, McCarthy JB. CSPG4, a Potential Therapeutic Target, Facilitates Malignant Progression of Melanoma. *Pigment Cell Melanoma Res.* 2011;24(6):1148-57. [PMCID:PMC3426219]
Impact Factor: 4.750 *Citation Index: 8*
45. Chi M, **Dudek AZ**. Vaccine therapy for metastatic melanoma: systematic review and meta-analysis of clinical trials. *Melanoma Res.* 2011;21(3):165-74.
Impact Factor: 2.254 *Citation Index: 9*
46. Jasinski P, Zwolak P, Terai K, Vogel RI, Borja-Cacho D, **Dudek AZ**. MT477 Acts in Tumor Cells as an AURKA Inhibitor and Strongly Induces NRF-2 Signaling. *Anticancer Res.* 2011;31(4):1181-7.
Impact Factor: 1.656 *Citation Index: 1*

Arkadiusz Dudek

47. Jilaveanu LB, Zito CR, Aziz SA, Chakraborty A, Davies MA, Camp RL, Rimm DL, **Dudek A**, Sznol M, Kluger HM. In vitro studies of dasatinib, its targets and predictors of sensitivity. *Pigment Cell Melanoma Res.* 2011;24(2):386-9.
Impact Factor: 4.750 *Citation Index: 5*
48. Jasinski P, Zwolak P, Isaksson Vogel R, Bodempudi V, Terai K, Galvez J, Land D, Dudek AZ. MT103 inhibits tumor growth with minimal toxicity in murine model of lung carcinoma via induction of apoptosis. *Invest New Drugs* 2011;29(5):846-52.
Impact Factor: 3.357 *Citation Index: 4*
49. Kluger HM, **Dudek AZ**, McCann C, Ritacco J, Southard N, Jilaveanu LB, Molinaro A, Sznol M. A phase 2 trial of dasatinib in advanced melanoma. *Cancer* 2011;117(10):2202-8. [PMCID:PMC3116034]
Impact Factor: 4.771 *Citation Index: 40*
50. Czech W, Dzwiniel W, Goryczka S, Arodz T, **Dudek AZ**. Exploring Complex Networks with Graph Investigator Research Application. *Computing and Informatics* 2011;30(2):381-410.
Impact Factor: 0.356 *Citation Index: 6*
51. Jasinski P, Zwolak P, Terai K, Borja-Cacho D, **Dudek AZ**. PKC-alpha inhibitor MT477 slows tumor growth with minimal toxicity in in vivo model of non-Ras-mutated cancer via induction of apoptosis. *Invest New Drugs* 2011;29(1):33-40.
Impact Factor: 3.357 *Citation Index: 3*
52. Bommakanti SV, **Dudek AZ**, Khatri A, Kirstein MN, Gada PD. Phase 1 Trial of Gemcitabine With Bortezomib in Elderly Patients With Advanced Solid Tumors. *Am J Clin Oncol.* 2010;34(6):597-602.
Impact Factor: 2.005 *Citation Index: 2*
53. Obulareddy SJ, Xin J, Truskinovsky AM, Anderson JK, Franklin MJ, **Dudek AZ**. Metanephric adenoma of the kidney: an unusual diagnostic challenge. *Rare Tumors* 2010;2(2):e38. [PMCID:PMC2994510]
Impact Factor: unknown *Citation Index: 0*
54. **Dudek AZ**. Endothelial lineage cell as a vehicle for systemic delivery of cancer gene therapy. *Transl Res.* 2010;156(3):136-46.
Impact Factor: 2.986 *Citation Index: 18*
55. Jirakulaporn T, Endrizzi B, Lindgren B, Mathew J, Lee PK, **Dudek AZ**. Capecitabine for skin cancer prevention in solid organ transplant recipients. *Clin Transplant.* 2010;25(4):541-8.
Impact Factor: 1.667 *Citation Index: 12*
56. Alam N, Gustafson KS, Ladanyi M, Zakowski MF, Kapoor A, Truskinovsky AM, **Dudek AZ**. Small-cell carcinoma with an epidermal growth factor receptor mutation in a never-smoker with gefitinib-responsive adenocarcinoma of the lung. *Clin Lung Cancer* 2010;11(5):E1-4.
Impact Factor: 2.944 *Citation Index: 12*
57. Powell SF, **Dudek AZ**. Treatment of melanoma-associated retinopathy. *Curr Treat Options Neurol.* 2010;12(1):54-63.
Impact Factor: 1.292 *Citation Index: 7*
58. Bodempudi V, Ohlfest JR, Terai K, Zamora EA, Vogel RI, Gupta K, Hebbel RP, **Dudek AZ**. Blood outgrowth endothelial cell-based systemic delivery of antiangiogenic gene therapy for solid tumors. *Cancer Gene Therapy* 2010;17(12):855-63.
Impact Factor: 2.802 *Citation Index: 5*
59. Antony GK, **Dudek AZ**. Interleukin 2 in Cancer Therapy. *Curr Med Chem* 2010;17(29):3297-302.
Impact Factor: 4.859 *Citation Index: 21*
60. Raza A, Franklin MJ, **Dudek AZ**. Pericytes and vessel maturation during tumor angiogenesis and metastasis. *Am J Hematol.* 2010; 85(8):593-8.
Impact Factor: 4.671 *Citation Index: 59*
61. Graziano SL, Gu L, Wang X, Tatum AH, Vollmer RT, Strauss GM, Kratzke R, **Dudek AZ**, Vokes EE, Green MR; Cancer and Leukemia Group B; North Central Cancer Treatment Group; Radiation Therapy Oncology Group. Prognostic significance of mucin and p53 expression in stage IB non-

- small cell lung cancer: a laboratory companion study to CALGB 9633. *J Thorac Oncol.* 2010;5(6):810-7. [PMCID:PMC2994510]
Impact Factor: 3.661 *Citation Index: 5*
62. Dudek AZ, Murthaiyah PK, Franklin M, Truskinovsky AM. Metastatic adamantinoma responds to treatment with receptor tyrosine kinase inhibitor. *Acta Oncologica* 2010;49(1):101-4.
Impact Factor: 3.137 *Citation Index: 2*
63. Antony GK, Bertino E, Franklin M, Otterson GA, **Dudek AZ**. Small cell lung cancer in never smokers: report of two cases. *J Thorac Oncol.* 2010;5(5):747-8.
Impact Factor: 3.661 *Citation Index: 5*
64. Powell SF, **Dudek AZ**. Treatment of Melanoma-Associated Retinopathy. *Curr Treat Option Neurol.* 2010;12(1):54-63.
Impact Factor: 1.292 *Citation Index: 8*
65. **Dudek AZ**, Yee RT, Manivel JC, Isaksson R, Yee HO. Carbonic anhydrase IX expression is associated with improved outcome of high-dose interleukin-2 therapy for metastatic renal cell carcinoma. *Anticancer Res.* 2010;30(3):987-92.
Impact Factor: 1.725 *Citation Index: 9*
66. Zwolak P, Manivel JC, Jasinski P, Kirstein MN, **Dudek AZ**, Fisher J, Cheng EY. Cytotoxic effect of zoledronic acid-loaded bone cement on giant cell tumor, multiple myeloma, and renal cell carcinoma cell lines. *J Bone Joint Surg Am.* 2010;92(1):162-8.
Impact Factor: 3.272 *Citation Index: 16*
67. Kamada P, **Dudek AZ**. Sorafenib Therapy for Metastatic Renal Carcinoma in Patients with Low Cardiac Ejection Fraction: Report of Two Cases and Literature Review. *Cancer Invest.* 2010; 28(5):501-4.
Impact Factor: 1.847 *Citation Index: 4*
68. Spector E, Franklin MJ, Truskinovsky AM, **Dudek AZ**. Sorafenib induces partial response in metastatic medullary thyroid carcinoma. *Acta Oncol.* 2010;49(1):104-6.
Impact Factor: 3.137 *Citation Index: 0*
69. Ettinger DS, Jotte R, Lorigan P, Gupta V, Garbo L, Alemany C, Conkling P, Spigel DR, **Dudek AZ**, Shah C, Slagia R, McNally R, Renschler MF, Oliver JW. Phase II Study of Amrubicin As Second-Line Therapy in Patients With Platinum-Refractory Small-Cell Lung Cancer. *J Clin Oncol.* 2010;28(15):2598-603.
Impact Factor: 18.372 *Citation Index: 46*
70. Powell S, **Dudek AZ**. Single-institution outcome of high-dose interleukin-2 (HD IL-2) therapy for metastatic melanoma and analysis of favorable response in brain metastases. *Anticancer Res.* 2009;29(10):4189-93.
Impact Factor: 1.725 *Citation Index: 8*
71. Oh S, Stish BJ, Sachdev D, Chen H, **Dudek AZ**, Vallera DA. A novel reduced immunogenicity bispecific targeted toxin simultaneously recognizing human epidermal growth factor and interleukin-4 receptors in a mouse model of metastatic breast carcinoma. *Clin Cancer Res.* 2009;15(19):6137-47. [PMCID:PMC2756320]
Impact Factor: 7.742 *Citation Index: 17*
72. Stish BJ, Oh S, Chen H, **Dudek AZ**, Kratzke RA, Vallera DA. Design and modification of EGF4KDEL 7Mut, a novel bispecific ligand-directed toxin, with decreased immunogenicity and potent anti-mesothelioma activity. *Br J Cancer* 2009;101(7):1114-23. [PMCID:PMC2768099]
Impact Factor: 5.042 *Citation Index: 13*
73. Thumbigere-Math V, Sabino MC, Gopalakrishnan R, Huckabay S, **Dudek AZ**, Basu S, Hughes PJ, Michalowicz BS, Leach JW, Swenson KK, Swift JQ, Adkinson C, Basi DL. Bisphosphonate-related osteonecrosis of the jaw: clinical features, risk factors, management, and treatment outcomes of 26 patients. *J Oral Maxillofac Surg.* 2009;67(9):1904-13.
Impact Factor: 1.500 *Citation Index: 27*

74. **Dudek AZ**, Lesniewski-Kmak K, Larson T, Dragnev K, Isaksson R, Gupta V, Maddaus MA, Kratzke RA. Phase II trial of neoadjuvant therapy with carboplatin, gemcitabine plus thalidomide for stages IIB and III non-small cell lung cancer. *J Thorac Oncol.* 2009;4(8):969-75.
Impact Factor: 3.661 *Citation Index: 9*
75. Wcislo R, Dzwiniel W, Yuen DA, **Dudek AZ**. A 3-D model of tumor progression based on complex automata driven by particle dynamics. *J Mol Model* 2009;15(12):1517-39.
Impact Factor: 1.871 *Citation Index: 10*
76. McTavish H, Griffin RJ, Terai K, **Dudek AZ**. Novel insulin-like growth factor-methotrexate covalent conjugate inhibits tumor growth in vivo at lower dosage than methotrexate alone. *Transl Res.* 2009;153(6):275-82.
Impact Factor: 2.903 *Citation Index: 2*
77. Murthaiah P, Truskinovsky AM, Shah S, **Dudek AZ**. Collision Tumor versus Multiphenotypic Differentiation: A Case of Carcinoma with Features of Colonic and Lung Primary Tumors. *Anticancer Res.* 2009;29(5):1495-7.
Impact Factor: 1.725 *Citation Index: 2*
78. **Dudek AZ**, Murthaiah PK, Franklin M, Truskinovsky AM. Metastatic adamantinoma responds to treatment with receptor tyrosine kinase inhibitor. *Acta Oncol.* 2009;1:1-4.
Impact Factor: 3.137 *Citation Index: 0*
79. Bodempudi V, Yamoutpoor F, Pan W, **Dudek AZ**, Esfandyari T, Piedra M, Babovick D, Woo RA, Mautner VF, Kluwe L, Clapp DW, Devries GH, Thomas SL, Kurtz A, Parada LF, Farassati F. Ral overactivation in malignant peripheral nerve sheath tumors. *Mol Cell Biol.* 2009;29(14):3964-74. [PMCID:PMC2704746]
Impact Factor: 5.527 *Citation Index: 12*
80. **Dudek AZ**, Zolnieriek J, Dham A, Lindgren BR, and Szczylik C. Sequential Therapy with Sorafenib and Sunitinib in Renal Cell Carcinoma. *Cancer* 2009;115(1):61-7.
Impact Factor: 4.771 *Citation Index: 108*
81. Powell SF, **Dudek AZ**. Tailoring treatment of nonsmall cell lung cancer by tissue type: role of pemetrexed. *Pharmgenomics Pers Med.* 2009;2:21-37. [PMCID:PMC3513199]
Impact Factor: not available *Citation Index: -*
82. **Dudek AZ**, Lesniewski-Kmak K, Shehadeh NJ, Pandey ON, Franklin M, Kratzke RA, Greeno EW, Kumar P. Phase I study of bortezomib and cetuximab in patients with solid tumours expressing epidermal growth factor receptor. *Br J Cancer* 2009;100(9):1379-84. [PMCID:PMC2694419]
Impact Factor: 5.042 *Citation Index: 20*
83. Leone JP, **Dudek AZ**. Enzyme replacement therapy for Gaucher's disease in patient treated for non-small cell lung cancer. *Anticancer Res.* 2008;28(6B):3937-9.
Impact Factor: 1.725 *Citation Index: 6*
84. Yamoutpour F, Bodempudi V, Park SE, Pan W, Mauzy MJ, Kratzke RA, **Dudek AZ**, Potter DA, Woo RA, O'Rourke DM, Tindall DJ, Farassati F. Gene silencing for epidermal growth factor receptor variant III induces cell-specific cytotoxicity. *Mol Cancer Ther.* 2008;7(11):3586-97.
Impact Factor: 5.226 *Citation Index: 18*
85. Jasinski P, Zwolak P, Terai K, **Dudek AZ**. Novel Ras pathway inhibitor induces apoptosis and growth inhibition of K-ras-mutated cancer cells in vitro and in vivo. *Transl Res.* 2008;152(5):203-12.
Impact Factor: 2.986 *Citation Index: 11*
86. **Dudek AZ** and Nguyen S. Safety of Nab-paclitaxel plus Sunitinib: Analysis of Three Cases. *Anticancer Res* 2008;28(5B):3099-105.
Impact Factor: 1.725 *Citation Index: 3*
87. Eisen T, Oudard S, Szczylik C, Gravis G, Heinzer H, Middleton R, Cihon F, Anderson S, Shah S, Bukowski R, Escudier B; TARGET Study Group (**Dudek AZ**). Sorafenib for older patients with renal cell carcinoma: subset analysis from a randomized trial. *J Natl Cancer Inst.* 2008;100(20):1454-63.
Impact Factor: 13.757 *Citation Index: 66*

88. Zwolak P, Jasinski P, Terai K, Gallus N, Ericson ME, Clohisy DR, and **Dudek AZ**. Addition of receptor tyrosine kinase inhibitor to radiation increases tumor control in an orthotopic murine model of breast cancer metastasis in bone. *Eur J Cancer* 2008;44(16):2506-17.
Impact Factor: 5.536 *Citation Index: 17*
89. Motzer RJ, Escudier B, Oudard S, Hutson TE, Porta C, Bracarda S, Grünwald V, Thompson JA, Figlin RA, Hollaender N, Urbanowitz G, Berg WJ, Kay A, Lebwohl D, Ravaud A; RECORD-1 Study Group (**Dudek AZ**). Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial. *Lancet* 2008;372(9637):449-56.
Impact Factor: 38.278 *Citation Index: 1142*
90. Whitson BA, Groth SS, Andrade RS, Garrett L, **Dudek AZ**, Jessurun J, Maddaus MA. Extension of survival by resection of asynchronous renal cell carcinoma metastases to mediastinal lymph nodes. *J Thorac Cardiovasc Surg.* 2008;135(5):1022-8.
Impact Factor: 3.406 *Citation Index: 4*
91. Jasinski P, Terai K, Zwolak P, **Dudek AZ**. Enzastaurin renders MCF-7 breast cancer cells sensitive to radiation through reversal of radiation-induced activation of protein kinase C. *Eur J Cancer* 2008;44(9):1315-22.
Impact Factor: 5.536 *Citation Index: 6*
92. **Dudek AZ**, Mescher MF, Okazaki I, Math VT, Luo X, Curtsinger JM, Miller JS. Autologous large multivalent immunogen vaccine in patients with metastatic melanoma and renal cell carcinoma. *Am J Clin Oncol.* 2008;31(2):173-81.
Impact Factor: 2.005 *Citation Index: 14*
93. **Dudek AZ**, Larson T, McCleod MJ, Schneider DJ, Dowell JE, Banerjee TK, Pandya KJ, Bromund JL, Chen R, Monberg MJ, Obasaju CK. Phase 1/2 Dose Escalating Study of Twice-Monthly Pemetrexed and Gemcitabine in Patients with Advanced Cancer and Non-small Cell Lung Cancer. *J Thorac Oncol.* 2008;3(4):394-9.
Impact Factor: 3.661 *Citation Index: 14*
94. **Dudek AZ**, Chereddy S, Nguyen S, Wagner JE, Maddaus M. Neoadjuvant Chemotherapy with Reduced-Dose Carboplatin and Gemcitabine for Non-small Cell Lung Cancer in a Patient with Fanconi Anemia. *J Thorac Oncol.* 2008;3(4):447-50.
Impact Factor: 4.040 *Citation Index: 2*
95. **Dudek AZ**, Zwolak P, Jasinski P, Terai K, Gallus NJ, Ericson ME, Farassati F. Protein kinase C- β inhibitor enzastaurin (LY317615.HCI) enhances radiation control of murine breast cancer in an orthotopic model of bone metastasis. *Invest New Drugs* 2008;26(1):13-24.
Impact Factor: 3.357 *Citation Index: 16*
96. Nguyen S, Franklin M, **Dudek AZ**. Skin ulcers in Klippel-Trenaunay syndrome respond to sunitinib. *Transl Res.* 2008;151(4):194-6.
Impact Factor: 2.986 *Citation Index: 2*
97. Jasinski P, Welsh B, Galves J, Land D, Zwolak, P, Ghandi L, Terai K, **Dudek AZ**. A novel quinoline, MT477: suppresses cell signaling through Ras molecular pathway, inhibits PKC activity, and demonstrates in vivo anti-tumor activity against human carcinoma cell lines. *Invest New Drugs* 2008;26(3):223-32.
Impact Factor: 3.357 *Citation Index: 25*
98. Subhadra C, **Dudek AZ**, Rath PP, Lee MS. Improvement in visual fields in a patient with melanoma-associated retinopathy treated with intravenous immunoglobulin. *J Neuroophthalmol.* 2008;28(1):23-6.
Impact Factor: 1.059 *Citation Index: 14*
99. Mulamalla K, Truskinovsky AM, **Dudek AZ**. Rare case of hemangiopericytoma responds to sunitinib. *Transl Res.* 2008;151(3):129-33.
Impact Factor: 2.986 *Citation Index: 15*
100. Dham A, Truskinovsky A.M, **Dudek AZ**. Thymic carcinoid responds to neoadjuvant therapy with sunitinib and octreotide: A Case Report. *J Thorac Oncol.* 2008;3(1):94-7.
Impact Factor: 3.661 *Citation Index: 6*


101. Arodz T, **Dudek AZ**. Multivariate Modeling and Analysis in Drug Discovery. Current Computer –Aided Drug Design 2007;3:240-7.
Impact Factor: 1.762 *Citation Index: 0*
102. **Dudek AZ**, Yunis C, Harrison L, Kumar S, Hawkinson R, Cooley S, Vasilakos JP, Gorski KS, Miller JS. First in human phase I trial of 852A a novel systemic Toll-Like Receptor 7 agonist to activate innate immune responses in patients with advanced cancer. Clin Cancer Res. 2007;13(23):7119-25.
Impact Factor: 7.742 *Citation Index: 44*
103. Zwolak P, **Dudek AZ**, Bodempudi V, Nguyen J, Hebbel RP, Gallus NJ, Ericson ME, Goblirsch MJ, and Clohisy DR,. Local irradiation in combination with bevacizumab enhances radiation control of bone destruction and cancer-induced pain in a model of bone metastases. Intl J Cancer 2007; 122(3):681-8.
Impact Factor: 5.444 *Citation Index: 10*
104. **Dudek AZ**, Larson T, Keshtgarpour M, Kumar P. Dose escalating study of biweekly gemcitabine and carboplatin in patients with advanced cancer. Am J Clin Oncol 2007;30(5):481-6.
Impact Factor: 2.005 *Citation Index: 2*
105. **Dudek AZ**, Bodempudi V, Milbauer L, Griffin RJ , Hebbel RP. Systemic Inhibition of Tumor Angiogenesis by endothelial cell-based gene therapy. Br J Cancer 2007;97(4):513-22. [PMCID:PMC2360342]
Impact Factor: 5.042 *Citation Index: 19*
106. Mitchell MS, Abrams J, Thompson JA, Kashani-Sabet M, DeConti RC, Hwu WJ, Atkins MB, Whitman E, Ernstoff MS, Haluska FG, Jakowatz JG, Das Gupta TK, Richards JM, Samlowski WE, Costanzi JJ, Aronson FR, Deisseroth AB, **Dudek AZ**, Jones VE. Randomized trial of an allogeneic melanoma lysate vaccine with low-dose interferon Alfa-2b compared with high-dose interferon Alfa-2b for Resected stage III cutaneous melanoma. J Clin Oncol. 2007;25(15):2078-85.
Impact Factor: 18.372 *Citation Index: 46*
107. Mullamala K, Truskinovsky AM, **Dudek AZ**. Pulmonary blastoma with renal metastasis responds to sorafenib. J Thor Oncol. 2007;2(4):344-7.
Impact Factor: 3.661 *Citation Index: 5*
108. Keshtgarpour M, **Dudek AZ**. SU-011248, a Vascular Endothelial Growth Factor Receptor-Tyrosine Kinase Inhibitor, controls chronic psoriasis. Transl Res. 2007;149(3):103-6.
Impact Factor: 2.986 *Citation Index: 12*
109. Kirstein MN, Moore MM, **Dudek AZ**. Review of selected Patents for Cancer Therapy Targeting Tumor Angiogenesis. Recent Pat Anti-Cancer Drug Discov. 2006;1(2):153-61.
Impact Factor: 2723 *Citation Index: 1*
110. **Dudek AZ**, Arodz T, Galvez, J. Computational Methods in Developing Quantitative Structure-Activity Relationships (QSAR): A Review. Comb Chem High Throughput Screen 2006;9(3):213-28.
Impact Factor: 1.903 *Citation Index: 114*
111. **Dudek AZ**, Mahaseth H. Hematopoietic stem cell transplant-related airflow obstruction. Curr Opin Oncol. 2006;18(2):115-9.
Impact Factor: 4.101 *Citation Index: 8*
112. Arodz T, Yuen DA, **Dudek AZ**. Ensemble of Linear Models for Predicting Drug Properties. J. Chem. Inf. Model 2006;46(1):416-23.
Impact Factor: 4.675 *Citation Index: 16*
113. **Dudek AZ**, Kmak KL, Koopmeiners J, Keshtgarpour M. Skin rash and bronchoalveolar histology correlates with clinical benefit in patients treated with gefitinib as a therapy for previously treated advanced or metastatic non-small cell lung cancer. Lung Cancer 2006;51(1):89-96.
Impact Factor: 3.434 *Citation Index: 37*
114. **Dudek AZ**, Mahaseth H. Circulating angiogenic cytokines in patients with advanced non-small cell lung cancer: correlation with treatment responses and survival. Cancer Invest. 2005;23(3):193-200.
Impact Factor: 1.847 *Citation Index: 67*

A. Dudek

115. Miller JS, Curtsinger J, Berthold M, Malvey K, Bliss RL, Le CT, Fautsch SK, **Dudek AZ**, Blazar BR, Panoskaltsis-Mortari A. Diminished neo-antigen response to keyhole limpet hemocyanin (KLH) vaccines in patients after treatment with chemotherapy or hematopoietic cell transplantation. *Clin Immunol.* 2005;117(2):144-51.
Impact Factor: 4.046 *Citation Index: 13*
116. Nesselova IV, Sham Y, **Dudek AZ**, van Eijk LI, Wu G, Slungaard A, Mortari F, Griffioen AW, Mayo KH. PF4 and IL8 CXC-chemokine heterodimer formation modulates function at the quaternary structural level. *J Biol Chem.* 2005;280(6):4848-58.
Impact Factor: 4.773 *Citation Index: 45*
117. **Dudek AZ**, Leśniewski – Kmak K, Bliss RL, Brunstein C, Condon DL, Kratzke RA. Pilot Phase II Study of Gemcitabine and Vinorelbine in Patients with Recurrent or Refractory Small Cell Lung Cancer. *Lung* 2005;183(1):43-52.
Impact Factor: 1.899 *Citation Index: 1*
118. **Dudek AZ**, Mahaseth H, DeFor TE, Weisdorf DJ. Bronchiolitis obliterans in chronic graft-versus-host disease: analysis of risk factors and treatment outcomes. *Biol Blood Bone Marrow Transpl.* 2003;9(10):657-66.
Impact Factor: 3.873 *Citation Index: 112*
119. **Dudek AZ**, Pawlak WZ, Kirstein MN. Molecular Targets in the Inhibition of Angiogenesis. *Expert Opin. Ther Targets* 2003;7(4):527-41.
Impact Factor: 3.716 *Citation Index: 14*
120. **Dudek AZ**, Verfaillie CM, Nesselova I, Mayo K, Pitchford S, Slungaard A. Platelet Factor 4 Promotes Adhesion of Hematopoietic Progenitors Cells And Binds Interleukin 8: Novel Mechanisms of Modulation of Hematopoiesis. *Blood* 2003 101(12):4687-94.
Impact Factor: 9.898 *Citation Index: 52*
121. Reyes M, **Dudek A**, Jahagirdar B, Koodie L, Marker PH, Verfaillie CM. Origin of endothelial progenitors in human postnatal bone marrow. *J Clin Invest.* 2003;109:337-46.
Impact Factor: 13.069 *Citation Index: 929*
122. Rocha-Lima CM, Savarese D, Bruckner H, **Dudek A**, Eckardt J, Hainsworth J, Yunus F, Lester E, Miller W, Saville W, Elfring GL, Locker PK, Compton LD, Miller LL, Green MR. Irinotecan Plus Gemcitabine Induces Both Radiographic and CA 19-9 Tumor Marker Responses in Patients with Previously Untreated Advanced Pancreatic Cancer. *J Clin Oncol.* 2002;20(5):1182-91.
Impact Factor: 18.372 *Citation Index: 96*
123. Gupta P, Oegema T, Brazil J, **Dudek A**, Slungaard A, Verfaillie C. Human LTC-IC Can Be Maintained For At Least 5 Weeks In Vitro When Interleukin-3 And A Single Chemokine Are Combined With O-sulfated Heparan Sulfates: Requirement For Optimal Binding Interactions Of Heparan Sulfate With Early-Acting Cytokines And Matrix Proteins. *Blood* 2000;95(1):147-55.
Impact Factor: 9.898 *Citation Index: 64*
124. Gupta P, Oegema, TR Jr, Brazil JJ, **Dudek AZ**, Slungaard A, Verfaillie CM. Structurally specific heparan sulfates support primitive human hematopoiesis by formation of a multimolecular stem cell niche. *Blood* 1998;92(12):4641-51.
Impact Factor: 9.898 *Citation Index: 99*
125. **Dudek AZ**, Pennell CA, Decker TD, Young TA, Key NS, Slungaard A. Platelet Factor 4 Binds To Glycanated Forms of Thrombomodulin and To Protein C; A Potential Mechanism for Enhancing a Generation of Activated Protein C. *J Biol Chem.* 1997; 272(50):31785-92.
Impact Factor: 4.773 *Citation Index: 39*

Editorials

1. Dudek AZ, Gupta K, Ramakrishnan S, and Mukhopadhyay D. Tumor Angiogenesis 2012. *J Oncol.* 2012;article ID,857383. <http://dx.doi.org/10.1155/2012/857383> [PMCID: PMC3419421]



Chapters in Books

1. M.N. Kirstein, **A.Z. Dudek**. Review of Selected Patents for Cancer Therapy Targeting. In: Tumor Angiogenesis Frontiers in Anti-Cancer Drug Discovery Volume 1 eISBN: 978-1-60805-161-8 pp.741-757 (17) doi: 10.2174/978160805161811001010741. *ROLE: Guarantor of integrity of entire study, Developed Study design, Defined intellectual content, Conducted literature research, Manuscript preparation, Manuscript editing, Manuscript review.*
2. **Dudek AZ**. Treatment of Metastatic Cancer. In: Devita, Hellman and Rosenberg's Cancer Review. Govindan, R. Hagerstwon: Lippincott Williams & Wilkins, 2009.


Presentations

Invited Presentations – INTERNATIONAL

1. "Lo Mejor de ASCO 2016- Melanoma, Immunotherapy of cancer", Trujillo, Peru, 9-10 September 2016
2. "Recent Advances in Management of Pancreatic Cancer" International Conference on Advances in Hematology and Oncology, August 28-19, 2015 Coeur d'Alene, Idaho
3. "Personalized management of lung cancer?" 13th Uruguayan Congress of Oncology, Montevideo, Uruguay, 22 November 2014
4. "Does immunotherapy bring a new era in treatment of lung cancer?" 13th Uruguayan Congress of Oncology, Montevideo, Uruguay, 22 November 2014
5. "Role of Transcription Factor FoxM1 and Tumor Suppressor ARF in Malignant Melanoma" 9th International Conference of Anticancer Research, Porto Carras, Greece, October 7-11, 2014
6. "Melanoma and Glioblastoma Multiforme 2011 ASCO Abstracts," Best of ASCO Ecuador-2011, Salinas, Ecuador, 07/29-30/2011.
7. "A phase II study of dasatinib in patients with previously treated malignant mesothelioma: CALGB 30601," International Mesothelioma Interest Group 2010, Kyoto, Japan, 08/31-9/3/2010.
8. "Large Multivalent Immunogen Vaccine in Patients with Metastatic Melanoma" and "Blood Outgrowth Endothelial Cell-based Delivery of Cancer Gene Therapy," 8th International Conference of Anticancer Research, Kos, Greece, 10/17-22/2008.
9. "Outcome of High-Dose Interleukin-2 Therapy for Metastatic Renal Cell Carcinoma: Single Institution Experience," 33rd ESMO Congress, Stockholm, Sweden, 09/12-16/2008.
10. "Outcome of High-Dose Interleukin-2 Therapy for Metastatic Renal Cell Carcinoma: Single Institution Experience," 33rd ESMO Congress, Stockholm, Sweden, 09/12-16/2008.
11. "Prognostic Significance of Molecular and Clinical Factors in Stage IB NSCLC: A Laboratory Companion Study to CALGB 9633," 12th World Conference on Lung Cancer, Seoul, South Korea, 09/2-6/2007.
12. "Phase II Trial of Neoadjuvant Therapy with Carboplatin, Gemcitabine plus Thalidomide for Stage II and IIIA Non-Small Cell Lung Cancer (NSCLC)," ESMO Conference (ECLU), Lugano, Switzerland, 07/5-8/2007.
13. "Biweekly Pemetrexed and Gemcitabine in Patients with Advanced Solid Tumors," 3rd European Spring Oncology Conference, Marbella, Malaga, Spain, 6/16-18/2005.
14. "Bronchiolitis Obliterans after Bone Marrow Transplantation," Polish Society of Hematology Meeting, Warsaw, Poland, 11/1999.

Invited Presentations – NATIONAL

1. "New Approaches to Lung Cancer: Translating Clinical Research into Clinical Practice," Iowa City, IA, 9/2006.
2. "Reducing Toxicities Associated with Treatment of Gastrointestinal Malignancies," Cytoprotection Institute for Education: Curriculum Workshop, Chicago, IL, 4/2006.




3. "Second Line Chemotherapy for Advanced Non-Small Cell Lung Cancer," Current Trends in Lung, Head and Neck Meeting, Detroit, MI, 4/2006.
4. "Modern Management of Non-Small Cell Lung Cancer," University of South Dakota, 11/2005.
5. "Novel Therapies of Lung Cancer," Mayo Clinic Lung Cancer Symposium, Rochester, MN, 4/2004.
6. "New Developments in the Treatment of Colorectal Cancer," The University of Texas, MD Anderson Cancer Center, Houston, Texas, 12/2003.
7. "The Impact of EGFR-TK Inhibition on Non-Small Cell Lung Cancer," University of South Dakota, Sioux Falls, SD, 11/2003.

Invited Presentations – LOCAL


1. "Tailoring Oncology Care with Genomics" Department of Medicine Grand Rounds, University of Illinois, 5/28/2013
2. "Individualized Medicine-Tailoring Patient Care with Genomic Profiling of Melanoma", 3rd Biennial Melanoma Patient Education Symposium, Mayo Clinic, Rochester, MN, May 18, 2013
3. "Management of Early Stage Non-Small Cell Lung Cancer," Internal Medicine Review and Update 2009, University of Minnesota, 11/12/2009.
4. "Management of Advanced Lung Cancer," Hennepin Medical Center, Minneapolis, Minnesota, 3/13/2008.
5. "Management of Advanced Malignant Melanoma," Department of Dermatology Grand Rounds, University of Minnesota, 1/9/2008.
6. "Targeted therapy in Ovarian Carcinoma," Division of Gynecologic Oncology Consensus Conference, University of Minnesota, 5/2007.
7. "Diagnosis Imaging and Treatment of C.N.S. Tumors," Internal Medicine Residency Core Conference, University of Minnesota, 12/2006.
8. "Management of Invasive and Metastatic Bladder Cancer," Urology Core Curriculum, University of Minnesota, 12/2006.
9. "Novel Gemcitabine Doublets in NSCLC Treatment," Novel Therapies in Thoracic Oncology, University of Minnesota, 11/2006.
10. "Malignant Pleural Mesothelioma," University of Minnesota, 10/2006.
11. "Modern Management of Kidney Cancer," University of Minnesota, 3/2006.
12. "Thoracic Oncology and Primary Care," University of Minnesota, 11/2005.
13. "Lung Cancer," Thoracic Oncology Conference, University of Minnesota, 10/2004.
14. "Hematopoietic Growth Factors: Indications and Use Guidelines," Internal Medicine Review & Update 2004, University of Minnesota, 10/2004.
15. "Novel Therapies in Thoracic Oncology," University of Minnesota, 9/2003.
16. "Thoracic Oncology and Primary Care," University of Minnesota, 3/2003.
17. "Novel Therapies in Thoracic Oncology," University of Minnesota, 10/2002.
18. "Family Practice Review: Screening for Lung Cancer," University of Minnesota, 5/2001.

Published Abstracts

1. Figlin R. A., Nicolette C. A., Amin A., **Dudek A.**, Logan T., Lance R. S., Holzbeierlein J. M., Pal S. K., Master V. A., DeBenedette M., Tcherepanova I.Y., Jain R., Williams W. L., Miesowicz F., Monesmith T. Monitoring T-cell responses in a phase II study of AGS-003, an autologous dendritic cell-based therapy in patients with newly diagnosed advanced stage renal cell carcinoma in combination with sunitinib. J Clin Oncol. 29: 2011 (suppl; abstr 2532)



2. Danesi H., **Dudek A.**, Spindler E., Alcorn Jr H.. Clinical evaluation of food effects on pharmacokinetics of the novel oral taxane, tesetaxel. J Clin Oncol. 29: 2011 (suppl; abstr e13059)
3. Ding L., Bliss R. L., Ingebrand M., Allen T., Ives P., **Dudek A.**, Kratzke R. A. Computer-aided volumetry analysis in assessing pulmonary chemotherapy response in advanced NSCLC comparing with RECIST criteria. J Clin Oncol. 29: 2011 (suppl; abstr 10593)
4. Powell S. F., Beitinjaneh A., Bliss R. L., Kratzke R. A., Leach J. W., **Dudek A.** Phase II study of topotecan and bevacizumab in advanced refractory non-small cell lung cancer (NSCLC). J Clin Oncol. 29: 2011 (suppl; abstr 7563)
5. Zwolak P., Borja-Cacho D., Phillips P., Dudeja V., Dawra R. K., Talukdar R., Chugh R. K., **Dudek A. Z.**, Vickers S. M., Saluja A. K.. Myricetin a novel natural antineoplastic agent decreases progression of human pancreatic cancer via inhibition of akt kinase and erk pathways. Abstract #: 558, 3rd Annual Academic Surgical Congress, February 13-15,2008, Huntington Beach, CA
6. **Dudek AZ**, Lesniewski-Kmak K, Koca N., Chereddy S., Maddaus, M, Dhlber P. Kratzke, R. Phase II Trial of Neoadjuvant Therapy with Carboplatin and Gemcitabine with Thalidomide in Patients with Stage IIB and IIIA Non-Small Cell Lung Cancer. 2007 ESMO Conference Lugano, Switzerland
7. Ready N, **Dudek AZ**, Wang XF, Graziano S, Green MR, Vokes EE. CALGB 30306: A phase II study of cisplatin, irinotecan and bevacizumab for untreated extensive stage small cell lung cancer. 2007 ASCO Annual Meeting Proceedings. Abstract 7563.
8. **Dudek AZ**, Gada P, Mullamala K, Shehadeh N. Phase I study of bortezomib plus cetuximab in patients with tumors expressing epidermal growth factor receptor. 2007 ASCO Annual Meeting Proceedings. Abstract 18143.
9. Dham A, **Dudek AZ**. Sequential Therapy with Sorafenib and Sunitinib in Renal Cell Carcinoma. 2007 ASCO Annual Meeting Proceedings. Abstract 5106.
10. Zwolak P, Manivel C, Jasinski P, Fisher J, Kirstein MN, **Dudek AZ**, Cheng EY. Zoledronic acid release from polymethylmethacrylate carrier and in vitro activity against giant cell tumor of bone. MSTs Meeting; November 10, 2006; Italy.
11. Zwolak P, Jasinski P, Farassati F, Thalhammer T, **Dudek AZ**. Selective protein kinase C- β inhibitor (Enzastaurin) suppresses tumor growth, bone osteolysis, cancer -induced bone pain, and enhance radiosensitivity of the bone tumor. AACR Molecular Diagnostics in Cancer Therapeutic Development: Maximizing Opportunities for Individualized Treatment, September 12-15, 2006; Chicago, IL
12. **Dudek AZ**, Larson T, McCleod M, Schneider DJ, Dowell JE, Ye Z, Cunneen J, Monberg M, Tai F, Obasaju CK. Initial results of a phase II study of biweekly pemetrexed and gemcitabine in patients with advanced NSCLC. J Clin Oncol., 2006 ASCO Annual Meeting Proceedings Part I. Vol 24, No. 18S (June 20 Supplement), 2006: 7128.
13. Jahan TM, Gu L, Wang X, Kratzke RA, **Dudek AZ**, Green MR, Vokes EE, Kindler HL. Vatalanib (V) for patients with previously untreated advanced malignant mesothelioma (MM): A phase II study by the Cancer and Leukemia Group B (CALGB 30107). J Clin Oncol., 2006 ASCO Annual Meeting Proceedings Part I. Vol 24, No. 18S (June 20 Supplement), 2006: 7081.
14. Mekhail T, Serwatowski P, **Dudek AZ**, Belani C, Jankowska R, Pandya KJ, Arnold S, Brahmer J, Gitlitz B, Govindan R. A phase II study of intravenous (IV) milataxel (M) for the treatment of non-small cell lung cancer (NSCLC) refractory to platinum-based therapy. J Clin Oncol., 2006 ASCO Annual Meeting Proceedings Part I. Vol 24, No. 18S (June 20 Supplement), 2006: 7098.
15. Kumar P, Keshtgarpour M, Kumar H, **Dudek AZ**. A phase I clinical study of biweekly carboplatin and gemcitabine in patients with advanced solid tumors. Journal of Clinical Oncology, 2006 ASCO Annual Meeting Proceedings Part I. Vol 24, No. 18S (June 20 Supplement), 2006: 12024.
16. **Dudek AZ**, Math V, Mescher M, Miller, J. Autologous large multivalent immunogen vaccine for the treatment of stage IV malignant melanoma and stage IV renal cell carcinoma. Proceedings of the ECCO, Abstract #513, 2005.
17. **Dudek AZ**, Yunis C, Kumar S, Harrison, L, Hawkinson R, Miller J. Immune Response Activation With a Toll-like Receptor 7 Agonist: Results of a Phase 1 Study. Meeting Proceedings of the ASCO, Abstract #2515, 2005.



18. Zwolak P, Goblirsch M, Nelson C, Clohisy DR, **Dudek AZ**. Anti-angiogenic therapy and local irradiation exhibit additive effects in decreasing tumor burden and reducing bone cancer pain.” J Bone Mineral Res. 20: P27-P28 Suppl. 2, 2005.
19. Zwolak P, Goblirsch P, Nelson N, Clohisy DR, **Dudek AZ**. Anti-angiogenic therapy and local irradiation exhibit additive effects in decreasing tumor burden and reducing bone cancer pain. “Skeletal Complications of Malignancy” Meeting in Bethesda, April 28-30, 2005.
20. **Dudek AZ**, Griffin R, Nelson CM, Ghandi L, Terai K, Ugaz E, Galvez J. Preclinical Evaluation of MT103, a postulated novel protein kinase C modulator: Validation of drug discovery methods based on molecular topology. Proceedings of the AACR, Abstract #3963, 2005.
21. Zwolak P, Nelson C, Goblirsch M, Clohisy DR. **Dudek AZ**. Therapy with antibody to VEGF in combination with megavoltage irradiation improves control of metastatic renal cell carcinoma of bone. Immune, vascular and gene targeting for cancer imaging and therapy-Meeting, San Diego, Feb. 28 - Mar. 2, 2005.
22. **Dudek AZ**, Bodempudi V, Nelson C, Chang L, Hebbel RP. Blood Outgrowth Endothelial Cells (BOEC) Contribute to Tumor Vascularization and Can Be Used for Delivery of Cancer Gene Therapy. Blood. 104(11):867a, Abstract #3173, 2004.
23. **Dudek A**, Marker P, Botner D, Hagen D, Chang L, Hebbel R. Anti-Angiogenic Therapy Delivered By Blood Outgrowth Endothelial Cells Reduces Tumor Vessel Number In Mice With Lewis Lung Carcinoma. Proceedings of the AACR, 2002.
24. **Dudek A**, Mahaseth H. Vascular Endothelial Growth Factor and Basic Fibroblast Growth Factor Levels Change After Chemotherapy In Non-Small Cell Lung Cancer Patients- Correlation with Tumor Response, Number Of Platelets, And Leukocytes. Proceedings of the AACR, 2002.

TEACHING AND CURRICULUM DEVELOPMENT

University of Illinois

2015-ongoing- College of Pharmacy BPS 539, Rotation Instructor

2014 –ongoing- College of Medicine Essential Technologies and Approaches in Translational Research

2014-ongoing- College of Pharmacy Colloquium BPS 385, Rockford

2014-ongoing- College of Pharmacy BPS/MDCH/PMPG 553, Chicago and Rockford

University of Minnesota

Curriculum Development

Ongoing, annual - Lectures, Department of Medicine (DOM) Grand Rounds, DOM Research Conferences, 1998-2012 Garibaldi (HOT Division research) Conferences

1998-2012 Radiation Oncology Residency Program Lectures “Lung Cancer”

2011-2012 Educational Curriculum Lectures for the Oncology Resident Elective “Lung Cancer”

2010 and 2011, MICa 8005 and 8013 class “Translational Cancer Research” lecturer. Title: “Phase I clinical trials and experimental therapeutics”

3/24/2010 Gynecological Oncology Fellowship Program “Female Genital Tract Melanoma”

2006 – Oncology Fellowship “Phase I and Phase II Clinical Trials”

2006 - Gynecology Residency Program “Phase I and Phase II Clinical Trials”

2006 – Dermatology Residency Program “Malignant Melanoma”

1998-2006 – Internal Medicine Residency Program, University of Minnesota, Oncology Lectures “Lung Cancer”

1998-2006– Oncology Fellowship, University of Minnesota, Oncology Lectures

“Malignant Melanoma”, “Kidney Cancer” and “Lung Cancer”

Thoracic Tumor Conference (weekly)

Malignant Melanoma Conference (monthly)

ADVISING AND MENTORING

Arkadiusz Z. Dudek

Graduate Student Activities

Masters' students

2010-2012–Javaid Sehrish, Master thesis, Oral Biology Program, Dental School, University of Minnesota.

Title: Molecular Abnormalities in Mucosal Melanoma.

2010 – Emily Craig Zabor, Master thesis, Biostatistics Plan B Committee, Division of Biostatistics, University of Minnesota.

Title: Adaptive Controlled Dose Escalation with Multiple Individual Covariates for Phase I Clinical Trials.

2010 – Ming Chi, Master's thesis, School of Public Health, University of Minnesota.

Title: Vaccine therapy for metastatic melanoma: systematic review and meta-analysis of clinical trials.

PhD students

2008-2012 – Math Thumbigere, PhD thesis, Oral Biology Program, Dental School, University of Minnesota.

Title: Bisphosphonate–Related Osteonecrosis of the Jaw. Currently postdoctoral fellow in Martha Somerman laboratory at NIH (NIDCR).

2009-2011 – Ali Khammanivong, PhD thesis, Oral Biology Program, Dental School, University of Minnesota.

Title: Regulatory Roles of Calprotectin in Head and Neck Squamous Cell Carcinogenesis.

2006-2010 – Peter Jasinski, Master thesis, University of Vienna, Austria.

Title: Protein kinase C as a Target for Cancer Therapy.

PhD thesis, Military Medical Institute, Warsaw, Poland.

Title: Preclinical Evaluation of Anti-cancer Activity of Novel Multi-Kinase Inhibitor.

2005-2007 – Tomasz Arodz, PhD thesis, University of Science and Technology, Cracow, Poland.

Title: Attention-shifting Strategies for Ensemble Pattern Recognition in Cancer Detection and Treatment Discovery.

Professional Student Activities

2014 – 2016 Hiral Shah, Oncology Fellow, Department of Medicine, University of Illinois.

Title: Clinical Cancer Research.

2013 – Stanley Borowicz, Oncology Fellow, Department of Medicine, University of Illinois.

Title: Clinical Cancer Research.

2013 – Rozina Chowdhery, Oncology Fellow, Department of Medicine, University of Illinois.

Title: Clinical Cancer Research.

2012-2013 – Chul Kim, Internal Medicine Resident,, Department of Medicine, University of Minnesota.
Title: Clinical Cancer Research.

2012-2013 – Tulasi Gummadi, Oncology Fellow, Department of Medicine, University of Minnesota.
Title: Clinical Cancer Research.

2006-2013 – Steven Powell, Internal Medicine Resident, Oncology Fellow, Department of Medicine, University of Minnesota.
Title: Clinical Cancer Research.

2009-2012 – Dylan Zylla, Oncology Fellow, Division of Hematology, Oncology, and Transplantation, Department of Medicine, University of Minnesota.
Title: Clinical Cancer Research.

2008-2011 – Satya Bommakanti, Oncology Fellow, Division of Hematology, Oncology, and Transplantation, Department of Medicine, University of Minnesota.
Title: Clinical Cancer Research.

2008-2009 – Amer Beitinjaneh, Oncology Fellow, Division of Hematology, Oncology, and Transplantation, Department of Medicine, University of Minnesota. (Private Practice)
Title: Phase II Study of Bevacizumab and Topotecan in NSCLC.

2004-2009 – Priya Kumar, Oncology Fellow, Adjunct Faculty (Community Physician), Division of Hematology, Oncology, and Transplantation, Department of Medicine, University of Minnesota.
Title: Clinical Cancer Research.

2006-2007 – Purvi Gada, Oncology Fellow, Division of Hematology, Oncology, and Transplantation, Department of Medicine, University of Minnesota. (Adjunct Faculty - Community Physician, U of M)
Title: Clinical Cancer Research.


2006-2007 – Anu Dham, Oncology Fellow, Division of Hematology, Oncology, and Transplantation, Department of Medicine, University of Minnesota.
Title: Clinical Cancer Research.

2005-2007 – Nauman Moazzam, Oncology Fellow, Division of Hematology, Oncology and Transplantation, Department of Medicine, University of Minnesota.
Title: Clinical Cancer Research.

Post-doctoral fellows supervised

2009-2010 – Andrew Stein, Postdoctoral Fellow, the Institute for Mathematics and its Applications, University of Minnesota.
Title: Mathematical Models of Tumor Response and Disease Survival.

2004-2009 – Paul Zwolak, Postdoctoral Research Associate, University of Minnesota
PhD thesis, Military Medical Institute, Warsaw, Poland



Title: Anti-tumoral Effect of Combined Radiation and Tyrosine Kinase Inhibitor in Model of Breast Cancer Metastases to Bone.

1999-2006 – Hemchandra Mahaseth, Postdoctoral Research Associate, University of Minnesota
Title: Circulating Angiogenic Cytokines in Patients with Advanced Non-Small Cell Lung Cancer.

Residents Supervised

2014 – Rohan Sharma, Internal Medicine Resident, Internal Medicine Advisor
2010 – Bryan Trottier, Internal Medicine Resident, Internal Medicine Advisor
2009 – Saqub Razzaque, Internal Medicine Resident, Internal Medicine Advisor

Other Mentoring Activities

2013 – Neeta Venepalli, Oncology Junior Faculty, Department of Medicine, University of Illinois.
Title: Clinical Cancer Research.
2010-2012 - Mentor, Minnesota Craniofacial Research Training Program, University of Minnesota Dental School

SERVICE AND PUBLIC OUTREACH

Service To The Discipline/Profession/Interdisciplinary Area(s)

Scientific Service

Conferences

9th International Conference of Anticancer Research, Porto Carras, Greece, October 7-11, 2014, Member of Organizing Committee.

UIC College of Medicine
Urban Health Program, Mentor 2014-current

Lung Cancer Session Co-chair Translational Research Approaches to Reduce Health Disparities in Lung Disease
University of Illinois, 9/10-11/2012.

UIC College of Medicine
Clinical Colloquium “Cancer Therapy Selected Clinical Cases”

Research Groups

2013-present Co-leader, Cancer Target and Therapeutics Program
University of Illinois Cancer Center
2012 Co-leader, Tumor Microenvironment
Masonic Cancer Center, University of Minnesota, School of Medicine
2011 – present Respiratory Committee, Member, Alliance
2011 – present Chair, Scientific Review Committee, Midwest Melanoma Partnership
2006 – 2012 Senior Member, Oral Biology Program, School of Dentistry, University of Minnesota.
2003 - 2012 Member, Vascular Biology Program, Department of Medicine, University of Minnesota
2003 - 2012 Leader, Phase 1 Team, Solid Tumor Oncology, CETI, Masonic Cancer Center, University of Minnesota
2003 - 2012 Co-Leader, Interdisciplinary Tumor Site Team for Melanoma, University of Minnesota
2009 - 2011 Member, Tumor Biology Program, University of Minnesota

2009 – 2011 Respiratory Committee, Cadre Member, Cancer and Leukemia Group B

Editorships/Journal Reviewer Experience

Editorial Boards

2007- present Editorial Board Member, The Open Cancer Journal
2006 - present Editorial Advisory Board member, Recent Patents on Anti-Cancer Drug Discovery
2010 and 2011 Invited Guest Editor, Special Issue Tumor Angiogenesis, Journal of Oncology


Ad Hoc Reviewer of Manuscripts

2010 - 2012 Journal of Thoracic Oncology
2008 - 2011 Blood
2006 - 2011 Translational Research
2005 - 2011 The American Journal of Clinical Oncology
2010 Annals of Oncology
2010 Investigational New Drugs
2008 - 2009 The American Journal of Pathology
2008 - 2009 British Journal of Cancer
2005 - 2009 Cancer Letter
2008 Gene Therapy
2007 Archives of Medical Research
2007 Acta Oncologica
2007 Journal of Clinical Oncology
2007 Cancer Chemotherapy and Pharmacology
2007 Cancer Immunology Immunotherapy
2005 - 2007 European Respiratory Journal
2006 American Journal of Physiology
2006 Cancer Causes and Control
2006 Mayo Clinic Proceedings
2006 The Journal of Laboratory and Clinical Medicine
2006 Oncology
2006 Combinatorial Chemistry & High Throughput Screening
2005 - 2006 Lung
2005 - 2006 The American Journal of Hematology
2005 - 2006 European Respiratory Journal

Review panels for external funding agencies, foundations, etc.

Invited Reviewer of National and International Grant Applications

2014 CDMRP Lung Cancer Concept Award
2013 CDMRP LCRP Clinical Exploration panel, chairman
2012 CDMRP Breast Cancer Clinical Translational Research Award
2011 James & Esther King Biomedical Research Program and the Bankhead-Coley Cancer Research Program, Florida Department of Health
2010 CDMRP BCRP Pathobiology
2010 CDMRP Lung Cancer Promising Clinician
2010 James & Esther King Biomedical Research Program and the Bankhead-Coley Cancer Research Program, Florida Department of Health
2009 CDMRP BCRP Pathobiology
2009 CDMRP PRMRP09 Mesothelioma Panel
2009 Hungarian Scientific Research Fund (OTKA)



Committee memberships

Committee and administrative work – National

- 2012 - present Co-Chair, Thoracic Oncology Working Group, Big Ten Cancer Research Consortium
- 2013 - present Steering Committee Member, Big Ten Cancer Research Consortium
- 2012 - present Alliance Respiratory Committee Member
- 2011 - present Chair, Scientific Review Committee, Midwest Melanoma Partnership
- 2006 - present Pancreatic Cancer Research Team Member,
- 2006 - 2011 Cancer and Leukemia Group B, Respiratory Committee Cadre Member

Service to the University/Medical School/Department

University of Minnesota

Medical School Service and Intercollegiate Service

Academic Health Center

- 1998 - 2012 Co-Chair, Thoracic Oncology Program, University of Minnesota Comprehensive Cancer Center
- 2010 – 2011 University of Minnesota Data Safety Monitoring Board member
- 2008 – 2011 University of Minnesota, Institutional Review Board member
- 2008 Ad Hoc protocol reviewer University of Minnesota GCRC
- 2005 Academic Health Center Research Service Organization Search Committee

Medical School

- 2007 Conflict of Interest Task Force, University of Minnesota
- 2006-2007 Radiation Oncology Development Committee, University of Minnesota
- 2006 Cancer Care Committee, University of Minnesota

Department/Unit Service

Division of Hematology, Oncology, and Transplantation


- 2005 - 2012 Division of Hematology, Oncology, and Transplantation Fellowship Committee
- 2005 - 2008 Director, Clinical Research; monthly meetings with University of Minnesota Cancer Center Clinical Trial Office staff regarding on-going clinical trials for treatment of cancer and patient accrual to these studies.

Masonic Cancer Center

- 2012 Member, Executive Committee, University of Minnesota, Masonic Cancer Center, University of Minnesota
- 2008 - 2012 – Leader, Solid Tumor Team, Cancer Experimental Therapeutics Initiative, Masonic Cancer Center, University of Minnesota

Community Outreach Activities

- 2009 - present Member, Academic Advisory Committee, Health, Technology, Innovation, Illinois Medical District
- 2009 - present Member, Board of Directors: A Breath of Hope Lung Foundation.
- 2011 - 2012 Speaker: Kidney Cancer Association
- 2011, June 20th Speaker: Bladder and Kidney Cancer Patient Education
- 2010, September 24th Speaker: Midwest Melanoma Symposium
- 2010, September 19th Speaker: Lungevity 5K Walk/Run
- 2013, April 16th, UI Cancer Center Outreach, Simeon Career Academy Visit to educate students on cancer research as a field of profession



2013, September 13th, Bridging the Gap: Emerging Health Issue in Underrepresented Minorities. “Lung Cancer in Minorities”

Updated – 03.13.2017 